Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
- PMID: 15111354
- DOI: 10.1093/annonc/mdh188
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
Abstract
Background: The aim of this study was to investigate the tolerability, pharmacokinetic interaction and antitumor activity of gefitinib ("Iressa", ZD1839), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, combined with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced solid tumors.
Patients and methods: This was an open-label feasibility trial evaluating two doses of gefitinib (250 and 500 mg/day) in combination with gemcitabine and cisplatin. Gefitinib was administered daily from day 2 onwards. Gemcitabine 1250 mg/m(2) was given on days 1 and 8 and cisplatin 80 mg/m(2) on day 1 for up to six 3-week cycles. Patients could then continue to receive gefitinib monotherapy.
Results: Eighteen patients were entered, nine at each gefitinib dose level. Two patients developed dose-limiting toxicity: one grade 3 convulsion (250 mg/day dose group) and one grade 3 rash (500 mg/day dose group). The most frequently occurring adverse events in the combination phase were vomiting (17 patients), asthenia (16), nausea (14), diarrhea (14) and skin rash (13). The most common grade 3/4 adverse events were vomiting (seven patients), asthenia (six), thrombocytopenia (six), diarrhea (five) and anorexia (five). Pharmacokinetic analyses showed no apparent pharmacokinetic interaction between gefitinib and cisplatin or gemcitabine, with the exception of a possible small increase in the geometric mean exposure to gemcitabine seen on day 8 of therapy when given alone with the higher dose of gefitinib. Of 17 evaluable patients, nine had confirmed partial responses, seven had stable disease and one had progressive disease.
Conclusions: Combination therapy of gefitinib with cisplatin and gemcitabine had a manageable and predictable safety profile, no major effect on exposure to any of the three drugs and antitumor activity.
Similar articles
-
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2. Cochrane Database Syst Rev. 2018. PMID: 29624208 Free PMC article. Review.
-
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium.Urol Int. 2016;96(1):5-13. doi: 10.1159/000381589. Epub 2015 Jun 6. Urol Int. 2016. PMID: 26068576 Clinical Trial.
-
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.BJU Int. 2008 Jan;101(1):20-5. doi: 10.1111/j.1464-410X.2007.07226.x. Epub 2007 Oct 8. BJU Int. 2008. PMID: 17922873 Clinical Trial.
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.J Clin Oncol. 2004 Mar 1;22(5):777-84. doi: 10.1200/JCO.2004.08.001. J Clin Oncol. 2004. PMID: 14990632 Clinical Trial.
-
Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.Clin Lung Cancer. 2003 Sep;5 Suppl 1:S18-21. doi: 10.3816/clc.2003.s.011. Clin Lung Cancer. 2003. PMID: 14641990 Review.
Cited by
-
Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase.Front Pharmacol. 2024 Jan 11;14:1231671. doi: 10.3389/fphar.2023.1231671. eCollection 2023. Front Pharmacol. 2024. PMID: 38273823 Free PMC article.
-
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.Acta Pharm Sin B. 2023 Sep;13(9):3583-3597. doi: 10.1016/j.apsb.2023.05.023. Epub 2023 May 23. Acta Pharm Sin B. 2023. PMID: 37719370 Free PMC article. Review.
-
Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters.Cancers (Basel). 2021 Nov 26;13(23):5963. doi: 10.3390/cancers13235963. Cancers (Basel). 2021. PMID: 34885072 Free PMC article.
-
Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.Front Endocrinol (Lausanne). 2021 Jun 21;12:605797. doi: 10.3389/fendo.2021.605797. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34234737 Free PMC article.
-
Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers.J Biomed Sci. 2021 Apr 8;28(1):24. doi: 10.1186/s12929-021-00719-5. J Biomed Sci. 2021. PMID: 33827580 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials